Encorafenib 75 mg in India - Improving Survival Rates in BRAF-Mutated Cancers
Encorafenib 75 mg capsules are a targeted therapy designed to improve survival rates in patients with BRAF-mutated cancers by inhibiting cancer cell growth. Encorafenib 75 mg in India is becoming a key option for effective treatment, supporting longe
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
E N D
Presentation Transcript
(+91) 8750275027 contact@impomedhealthcare.com C-70, SECOND FLOOR OFFICE -A, DDA SHEDS, OKHLA INDUSTRIAL AREA, PHASE- 1, NEW DELHI-110020. Home Who We Are What We Do Diseases Treatment FAQs Contact Us ENCORAFENIB Home | Cancer | Solid Tumors | ENCORAFENIB ENCORAFENIB Capsules Description Composition Dosage Indications Contact Us ENCORAFENIB 50 MG AND 75 MG CAPSULES BRAFTOVI (encorafenib) is a kinase inhibitor. BRAFTOVI (encorafenib) capsules for oral use contain 50 mg or 75 mg of encorafenib with the following inactive ingredients: copovidone, poloxamer 188, microcrystalline cellulose, succinic acid, crospovidone, colloidal silicon dioxide, magnesium stearate (vegetable origin). The capsule shell contains gelatin, titanium dioxide, iron oxide red, iron oxide yellow, ferrosoferric oxide, monogramming ink (pharmaceutical glaze, ferrosoferric oxide, propylene glycol). C-70, SECOND FLOOR OFFICE -A, DDA SHEDS, OKHLA INDUSTRIAL AREA, PHASE- 1, NEW DELHI-110020. +91-9007090388 +91-8750275027 contact@impomedhealthcare.com rahman@impomedhealthcare.com mohan.singh@impomendhealthcare.com Quick Links Diseases Corporate O?ce Home Who We Are What We Do Treatment FAQs Contact Us Blog Cancer Neurology Endocrinology Miscellaneous C-70, SECOND FLOOR OFFICE -A, DDA SHEDS, OKHLA INDUSTRIAL AREA, PHASE- 1, NEW DELHI-110020. , +91-8750275027 +91-9007090388 Established in New Delhi, India in 2020, ImpoMed Healthcare has grown over the years from a new start up to one of the Most Preferred Company for Facilitation of the USFDA/European FDA Approved. contact@impomedhealthcare.com rahman@impomedhealthcare.com Imported Drugs-Only mohan.singh@impomendhealthcare.com Follow us on: Copyright 2024 ImpoMed
